BSX — Boston Scientific · catalysts, narrative & risks

Below is a synthesis drawn from the new sources [1]–[29], cross-checked against the internal library [LIB-n] and the first-party company file [DOC-n]. I note where sources disagree or reflect different dates, and I flag the April vs. July guidance cuts, which are commonly conflated.

Note on background: BSX's listing (NYSE) and its classification under medical_devices are our own universe inputs, so I am not re-deriving or reporting them as findings here.

Recent catalysts (roughly late June – late September 2026)